- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05480358
Clinical Trial of a Low Protein Diet in Patients With Cognitive Impairment
Phase I/II Randomized Clinical Trial of a Low Protein Diet in Patients With Cognitive Impairment
Study Overview
Status
Intervention / Treatment
Detailed Description
Cognitive impairment that exceeds the physiological decline associated with aging can take the form of mild cognitive impairment (MCI) or, in its most severe form, dementia. In turn, patients diagnosed with MCI evolve towards outright Alzheimer's disease (AD) in an estimated percentage of 15%/year. MCI can occur in the form of amnestic MCI (amnestic MCI, aMCI; by far the most common) or non-amnestic MCI (single or multiple domain), where amnestic is the form that most frequently evolves into AD. Therefore this clinical trial will focus on the latter (as well as on the AD). Diet cycles with low sugar and protein levels followed by diets with normal levels of these lead to temporary reductions in growth hormone and IGF-1 levels. Both are potential mediators of the neuroprotective and regenerative effects of these diets not only in mice, but also in monkeys and humans . However, heavily restricted diets in terms of calories are often difficult to endure over time and are frequently associated with side effects, even significant ones and with progressive weight loss, in particular of lean mass. In a mouse model of AD, it has been shown that periodic cycles of a "fasting-mimicking" diet (FMD) restricted in protein content (PR-FMD) but not in terms of calories are able to reduce levels plasma levels of IGF-1 with contrasting effects on the neurodegeneration process. In particular, such FMD has been shown to reduce by about 30-70%, the levels of hyperphosphorylated tau protein (one of the typical markers of AD) at the hippocampal level, reducing the age-related deficit of cognitive performance. A relevant neuroregenerative effect (associated with a clinical improvement in motor coordination and memory) has been demonstrated in mice subjected to a diet based on a similar DMD during their "average life" (months 16-30).
It is proposed to conduct a study of twelve monthly cycles of the ProlonADTM diet (by L-Nutra) in patients with aMCI or mild AD (MMSE 18-23) diagnosed according to the criteria defined by Peterson and McKahn, respectively (1, 3 ).
It is proposed to conduct a randomized clinical trial of twelve monthly cycles of the ProlonADTM diet (by L-Nutra) vs. placebo diet in patients with aMCI or mild AD (MMSE 18-23). Patients in the treatment group alone will also receive a range of supplements containing omega-3 fatty acids, caffeine, tree nuts, coconut oil, olive oil and cocoa - which will be supplied with the ProlonADTM diet kit. Patients assigned to both arms will also receive personalized dietary recommendations matched to instructions for light-moderate physical activity to be carried out also at home and aimed, especially in the case of patients assigned to receive ProlonADTM, to prevent the loss of lean mass. The primary endpoint of the study will be the feasibility and safety of the twelve cycles of ProlonADTM. Feasibility is defined as taking at least one course of DMD every two months with the option of admitting consumption of 50% of the planned diet and / or a maximum consumption of 10 Kcal / kg of unforeseen food in only one of days 1-5 of each cycle. Investigators speculate that ProlonADTM will not cause severe side effects and that it will have no detrimental effect on the patient's body composition, specifically in terms of impact on lean mass measured by dynamometry and bioimpedance analysis.
Secondary objectives will include:
- conversion rate to AD (for patients with aMCI);
- episodic memory evaluated with Free and Cued Selective Reminding Test (FCRST);
- cognitive status assessed by MMSE, CDR-Sum of the boxes;
- functional status assessed with Barthel Index, IADL;
- emotional state assessed using the CESD-R scale;
- nutritional status (MNA and body composition - bioimpedance, handgrip);
- caregiver stress assessed through Caregiver Burden Inventory and NPI;
- quality of life of patients (QLQ-AD);
- inflammatory markers, oxidative stress markers, neuronal damage markers (Neurofilament Light, NfL), quantification of circulating stem cells, cell aging markers (eg evaluation of the telomerase activity of lymphocytes).
- assessment of frailty (Rockwood frailty index, which also includes walking speed, handgrip, breathing capacity)
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Genova, Italy
- Recruiting
- Ospedale Policlinico San Martino
-
Contact:
- Alessio Nencioni
- Phone Number: +390103538990
- Email: alessio.nencioni@unige.it
-
Perugia, Italy
- Recruiting
- Azienda Ospedaliera di Perugia
-
Contact:
- Patrizia Mecocci
- Phone Number: +390755783839
- Email: patrizia.mecocci@unipg.it
-
-
GE
-
Genoa, GE, Italy, 16132
- Recruiting
- Alessio Nencioni
-
Contact:
- Alessio Nencioni, MD
- Phone Number: 8990 +39 010 353
- Email: alessio.nencioni@unige.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 55-80;
- Presence of aMCI or initial AD (MMSE 18-23);
- Normal organ function (liver and kidney);
- BMI not less than 20 kg/m2;
- Bioimpedance phase angle (PA) > 5 °;
- Adherence to informed consent
Exclusion Criteria:
- Age> 80 years
- Diabetes mellitus;
- Organ impairment (liver, kidney);
- Food allergies to the components of ProlonADTM;
- Patients on therapy with vitamin K antagonist anticoagulants;
- PA <5 °;
- Patients who live alone or are not adequately supported by the family context;
- Other experimental therapies in progress.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo diet
One meal which substitute or lunch or dinner for 5 days, without calories restriction.
|
Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days.
Day 1 of Prolon provides ~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide ~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
|
Experimental: ProlonADTM
The ProlonADTM diet, which will be taken by the patient once a month for 5 days, is a low-calorie and low-protein diet, and provides all the micronutrients necessary to avoid malnutrition.
The diet will be performed in twelve consecutive months.
The components of the diet will be approximately 30% calorie restricted and 50% protein restricted but supplemented with 50% of the RDA in vitamins and minerals and also supplemented with both nonessential and essential amino acids identified in animal studies to be effective.
Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days.
Day 1 of Prolon provides ~4600 kJ (11% protein, 46% fat, and 43%carbohydrate), whereas days 2-to-5 provide ~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
|
Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days.
Day 1 of Prolon provides ~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide ~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: 12 months
|
Safety of FMD in terms of percentage of patients experiencing adverse events and/or worsening of nutritional status. To obtain clinical data on safety of the FMD in MCI or AD patients as assessed by percentage of patients (%) experiencing > grade 3 adverse events and/or a significant decrease in their lean body mass (kg) and/or with a reduction of phase angle <5° assessed with bio-impedance measurements. |
12 months
|
Percentage of patients able to achieve the designated diet regimen
Time Frame: 12 months
|
Feasibility of FMD in terms of percentage of patients able to complete the diet regimen To evaluate the feasibility of the FMD in MCI and AD patients as assessed by the percentage of patients (%) able to achieve the designated diet regimen.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of the FMD in terms of conversion rate to AD
Time Frame: 12 months
|
Efficacy of the FMD in terms of coversion rate to AD will be assessed with the conversion rate (%) from AD to aMCI
|
12 months
|
Efficacy of the FMD in terms of functional state
Time Frame: 12 months
|
Efficacy of the FMD in terms of functional will be assessed with Barthel Index (BI) from 0 as the worse score and 100 as the best score.
|
12 months
|
Efficacy of the FMD in terms of emotional state
Time Frame: 12 months
|
Efficacy of the FMD in terms of emotional state will be assessed with the Center for Epidemiologic Studies Depression Scale Revised (CESD-R) with 0 as the best score and 80 as the worse score.
|
12 months
|
Efficacy of the FMD in terms of nutritional state
Time Frame: 12 months
|
Efficacy of the FMD in terms of nutritional state will be assessed with phase angle with bioimpedance (°)
|
12 months
|
Efficacy of the FMD in terms of caregiver stress' level
Time Frame: 12 months
|
Caregiver stress will assessed through Caregiver Burden Inventory (CBI) with 0 as the best score and 96 as the worse score
|
12 months
|
Efficacy of the FMD in terms of quality of life
Time Frame: 12 months
|
Efficacy of the FMD in terms of quality of life of patients with Quality of Life AD (QLQ-AD) with 13 as the worse score and 52 as the best score.
|
12 months
|
Efficacy of the FMD in terms of prevention of Frailty
Time Frame: 12 months
|
Efficacy of the FMD in terms of prevention of Frailty with 40-item Rockwood frailty index (FI) with 0 as the best score and 1 as the worse score.
|
12 months
|
Efficacy of the FMD in terms of alzheimer and inflammatory biomarkers
Time Frame: 12 months
|
We will assess the inflammatory markers, oxidative stress markers, neuronal damage markers (Neurofilament Light, NfL), quantification of circulating stem cells, cell aging markers (eg evaluation of the telomerase activity of lymphocytes)
|
12 months
|
Efficacy of the FMD in terms of episodic memory
Time Frame: 12 months
|
Efficacy of the FMD in terms of episodic memory will evaluated with Free and Cued Selective Reminding Test (FCRST) with a range from 0 as worse score to 36 as best score.
|
12 months
|
Efficacy of the FMD in terms of general cognitive status
Time Frame: 12 months
|
Efficacy of the FMD in terms of general cognitive status with mini-mental state examination (MMSE) with 0 as worse score and 30 as the best score.
|
12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FMD AD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
University of California, San FranciscoNational Institute on Aging (NIA)RecruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.RecruitingMild Cognitive Impairment (MCI)Taiwan
-
Thomas Jefferson UniversityJohns Hopkins University; University of Pennsylvania; National Institute on Aging... and other collaboratorsCompletedMild Cognitive Impairment (MCI)United States
-
Palo Alto Veterans Institute for ResearchU.S. Army Medical Research and Development CommandCompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Assaf-Harofeh Medical CenterNeurim Pharmaceuticals Ltd.UnknownMild Cognitive Impairment (MCI)Israel
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedAmnestic Mild Cognitive ImpairmentUnited States
-
Meir Medical CenterTerminatedMild Cognitive Impairment (MCI)Israel
Clinical Trials on Fasting-Mimicking Diet ProlonADTM
-
Indiana UniversityCompletedNon-small Cell Lung CancerUnited States
-
Leiden University Medical CenterHealth Holland; Dutch Diabetes Research Foundation; IFOM, The FIRC Institute... and other collaboratorsCompletedDiabetes Mellitus, Type 2Netherlands
-
Galway ClinicUnknownMetabolic Syndrome | Prostate Cancer | Intermittent FastingIreland
-
National Nutrition and Food Technology InstituteRecruitingLeukemia | Fasting Mimicking DietIran, Islamic Republic of
-
University of SalentoActive, not recruitingPolycystic Ovarian SyndromeItaly
-
University of Campinas, BrazilUnknown
-
Azienda Ospedaliera Universitaria Policlinico Paolo...University of Palermo; Centro Studi Psicoterapia Neo-FunzionaleCompleted
-
Stanford UniversityRecruitingDiet Modification | Ulcerative Colitis | Inflammatory Bowel DiseaseUnited States
-
University of Southern CaliforniaCompleted
-
Fudan UniversityChanghai Hospital; Shanghai Zhongshan Hospital; Huashan Hospital; Tongji Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine and other collaboratorsRecruitingColorectal Cancer | Fasting Mimicking DietChina